Related Experiment Video

Updated: Apr 22, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.4K

Genome-wide association study of medication adherence in chronic diseases in the korean population

Incheol Seo1, Seong-Il Suh1, Min-Ho Suh1

  • 1Department of Microbiology, Keimyung University School of Medicine, Daegu 704-701, Korea.

Genomics & Informatics
|October 16, 2014
PubMed

Insights

Medication adherence, crucial for chronic disease management, shows genetic links. A genome-wide study found suggestive associations near the GCC1 gene, potentially influencing adherence behavior.

Area of Science:

  • Genetics
  • Pharmacology
  • Behavioral Science

Background:

  • Medication adherence is vital for managing chronic diseases like hypertension and diabetes, yet non-adherence rates average 50%.
  • Understanding the genetic underpinnings of medication adherence can inform strategies to improve patient outcomes.
  • Previous research has linked decision-making capabilities to genetic factors in substance abuse.

Purpose of the Study:

  • To investigate the genetic basis of medication adherence in patients with chronic diseases.
  • To identify single nucleotide polymorphisms (SNPs) associated with medication adherence using a genome-wide association study (GWAS).

Main Methods:

  • A genome-wide association study (GWAS) was performed on data from the Korean Association Resource project.
  • The study included 235 medication non-adherents and 1,067 medication adherents with hypertension or diabetes, based on self-reported adherence.
  • Statistical analyses identified SNPs associated with medication adherence.

Main Results:

  • Four SNPs showed suggestive genome-wide associations with medication adherence.
  • The most significant SNP, rs6978712, located near the GCC1 gene, was identified (p = 4.87 × 10(-7)).
  • Three loci, including rs6978712 and two in strong linkage disequilibrium, showed potential association with adherence behavior, possibly related to decision-making.

Conclusions:

  • Genetic factors, particularly those near the GCC1 gene, may play a role in medication adherence behavior.
  • Further research is warranted to explore the association between GCC1 gene loci and medication adherence.
  • Standardized phenotype criteria for self-reported adherence are needed for future replication studies.

Keywords:
chronic diseasegenome-wide association studymedication adherencemedication compliance

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.1K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
387
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
152
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
239
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
225